Cell Therapeutics to Conduct Full Analysis Under Phase III Trial Following Discussions With FDA

Thursday, Cell Therapeutics, Inc. said that following the discussions with the U.S. Food and Drug Administration regarding its EXTEND trial for patients with aggressive non-Hodgkin’s lymphoma the Company has decided to conduct a full analysis of the trial instead of an interim analysis as previously planned.
Trading Markets